BDBM159102 US10093663, Example 4b::US9682968, Example-3

SMILES COC1CCN(Cc2c(C)cc(C)c3[nH]ccc23)C(C1)c1ccccc1

InChI Key

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 159102   

TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  6nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  6.00E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  6.70E+4nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  6.80E+4nMAssay Description:Inhibition of human serine protease factor B by TR-FRET based competition binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  1.40E+3nMAssay Description:Inhibition of human serine protease factor B catalytic domain (D470 to L764 residues) assessed as inhibition of cleavage cobra venom factor (CVF):Bb ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  1.40E+3nMAssay Description:Inhibition of human serine protease factor B catalytic domain (D470 to L764 residues) assessed as inhibition of cleavage cobra venom factor (CVF):Bb ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  6.80E+4nMAssay Description:Inhibition of human serine protease factor B by TR-FRET based competition binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  720nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent